JChem Instant JChem Publication

Novel anti-prostate cancer scaffold identified by the combination of in silico and cell-based assays targeting the PI3K-AKT-mTOR pathway

Posted by

on 2019-09-12

JChem Instant JChem Publication

Novel anti-prostate cancer scaffold identified by the combination of in silico and cell-based assays targeting the PI3K-AKT-mTOR pathway

Phenotypic assays were performed in prostate cancer cell lines to describe the biological activity of PI3K-AKT-mTOR pathway inhibitors retrieved from the virtual screening initiative. These novel chemicals share in common the aminopyridine scaffold, hitting PC-3 cells in macromolar range, with selectivity index over fibroblast cell lines. Moreover, a preliminary study of the mode of action by flow cytometry assay pointed out that these compounds had a rapamycin-like response for the PI3K-AKT-mTOR pathway modulation.

Visit the publication

Facebook Twitter LinkedIn

Copy to clipboard Copy link

Visit the publication

Marvin

The new Marvin is a universal chemical editor that serves the needs of any chemist involved in research and drug discovery.

Design Hub

A compound design and tracking platform for drug discovery teams and their external collaborators that connects scientific hypotheses, candidate compound selection and computational capabilities.

Compound Registration

Compound Registration compares the uniqueness of new small molecules against those already stored in your database.

Design Hub

Novel anti-prostate cancer scaffold identified by the combination of in silico and cell-based assays targeting the PI3K-AKT-mTOR pathway

Novel anti-prostate cancer scaffold identified by the combination of in silico and cell-based assays targeting the PI3K-AKT-mTOR pathway

Related content

Predicting pKa

Coupling stabilizers open KV1-type potassium channels

Cheminfo Stories 2021 Virtual UGM Asia Pacific Edition: Design of new compounds from the available chemical space

Responding to the Challenge Posed by the Generic Control of Substances